Although accumulating genetic evidence suggests that HDL cholesterol concentration is unlikely to be causally related to CHD [7–9], there were 2 strong reasons to believe that CETP inhibition may still reduce vascular risk: (i) genetic studies of CETP variants have shown associations with CHD [10,11] and (ii) some CETP inhibitors not only increase HDL cholesterol but also appear to lower LDL cholesterol as measured by conventional assays [12,13]. Here, CETP is linked to coronary artery disorder.